BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:46 PM
 | 
Aug 31, 2009
 |  BC Extra  |  Top Story

Pradaxa tops warfarin in AF trial

Boehringer Ingelheim GmbH (Ingelheim, Germany) said the Phase III RE-LY trial in 18,113 patients with non-valvular atrial fibrillation (AF) at moderate to high risk of stroke showed that both doses of Pradaxa dabigatran met the primary endpoint of non-inferiority...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >